Nyxoah: The Future Of OSA
Nyxoah's Genio implant is poised to revolutionize Obstructive Sleep Apnea treatment, with FDA approval expected in Q1 2025 acting as a potential catalyst for shares. Nyxoah, founded by Robert Taub, is led by Olivier Taelman and focuses on the Genio implant, which offers a less intrusive alternative to CPAP and Inspire Therapy. Despite a high burn rate, Nyxoah has sufficient cash reserves to last until 2026, with U.S. market entry expected to significantly boost revenue post-FDA approval.
Nyxoah S.A. (NYXH) Q3 2024 Earnings Call Transcript
Nyxoah S.A. (NASDAQ:NYXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and IR Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Adam Maeder - Piper Sandler Joe Federico - Stifel Suraj Kalia - Oppenheimer Ross Osborn - Cantor Fitzgerald David Rescott - Baird Operator Good day.
Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates
Nyxoah SA (NYXH) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.29 per share a year ago.
Nyxoah SA (NYXH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Nyxoah (NYXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nyxoah S.A. (NYXH) Q2 2024 Earnings Call Transcript
Nyxoah S.A. (NASDAQ:NYXH ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and Investor Relations Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Suraj Kalia - Oppenheimer Edward White - H.C.
Nyxoah SA (NYXH) Reports Q2 Loss, Misses Revenue Estimates
Nyxoah SA (NYXH) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago.
HC Wainwright Research Analysts Cut Earnings Estimates for Nyxoah S.A. (NASDAQ:NYXH)
Nyxoah S.A. (NASDAQ:NYXH – Free Report) – Investment analysts at HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for shares of Nyxoah in a report released on Wednesday, May 15th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($0.52) for the quarter, down from their previous estimate of ($0.47). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Nyxoah’s current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Nyxoah’s Q3 2024 earnings at ($0.45) EPS, Q4 2024 earnings at ($0.41) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($1.25) EPS and FY2026 earnings at $0.05 EPS. Several other equities research analysts have also recently issued reports on the company. Oppenheimer lowered their price objective on Nyxoah from $20.00 to $15.00 and set an “outperform” rating on the stock in a report on Wednesday, May 15th. Piper Sandler raised their target price on shares of Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Stifel Nicolaus reissued a “buy” rating and issued a $27.00 target price on shares of Nyxoah in a research note on Wednesday, May 15th. Finally, Cantor Fitzgerald decreased their target price on shares of Nyxoah from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 15th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.20. View Our Latest Stock Report on NYXH Nyxoah Stock Down 3.2 % NASDAQ:NYXH opened at $10.10 on Monday. Nyxoah has a 52 week low of $4.00 and a 52 week high of $20.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.50 and a current ratio of 3.94. The stock’s 50-day moving average price is $11.96 and its 200-day moving average price is $9.12. Nyxoah (NASDAQ:NYXH – Get Free Report) last posted its earnings results on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.48%. The firm had revenue of $1.96 million for the quarter, compared to analysts’ expectations of $2.01 million. Institutional Trading of Nyxoah An institutional investor recently bought a new position in Nyxoah stock. Ikarian Capital LLC purchased a new stake in Nyxoah S.A. (NASDAQ:NYXH – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 50,699 shares of the company’s stock, valued at approximately $684,000. Nyxoah Company Profile (Get Free Report) Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
